Company Description

20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases.

It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers.

It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups.

The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025.

The company was incorporated in 2000 and is based in Gaithersburg, Maryland.

20/20 Biolabs, Inc.

Country	United States
Founded	2000
Industry	Medical Devices
Sector	Healthcare
Employees	14
CEO	Jonathan Cohen

Contact Details

Address: 15810 Gaither Road, Suite 235 Gaithersburg, Maryland 20877 United States
Phone	240 453 6339
Website	2020biolabs.com

Stock Details

Ticker Symbol	AIDX
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	1139685
CUSIP Number	90138K101
ISIN Number	US90138K1016
Employer ID	52-2272107
SIC Code	8734

Key Executives

Name	Position
Jonathan Cohen	Founder, Chief Executive Officer, President and Director
Dr. Jiming Zhou Ph.D.	Chief Operating Officer
Dr. Michael Saul Lebowitz Ph.D.	Chief Scientific Officer
Alan B. Bergman	Chief Financial Officer
David Lees	Director of Sales
Ronald R. Baker	Chief Business Officer
Marc Gordon	Controller

Latest SEC Filings

Date	Type	Title
Sep 18, 2026	8-K	Current Report
Sep 10, 2026	8-K	Current Report
Sep 2, 2026	8-K	Current Report
Aug 19, 2026	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Aug 19, 2026	8-K	Current Report
Aug 17, 2026	424B3	Prospectus
Aug 17, 2026	424B3	Prospectus
Aug 17, 2026	8-K	Current Report
Aug 14, 2026	10-Q	Quarterly Report
Aug 5, 2026	8-K	Current Report

View All SEC Filings